Elevance Health excels with Q4 2023 revenues of $42.45B, up 7% YoY, surpassing consensus. Explore the growth drivers, profit insights, and future projections.
Walgreens' strategic move: Potential $4 billion sale of Shields Health Solutions, part of a broader financial strategy. CEO Tim Wentworth addresses challenges and cost-cutting measures.
"I'm not a religious person. I don't subscribe to any of the religions, but I felt the voice of god. I felt a deep resonance in me," the younger Musk told Asprey, adding that he wasn't sure at the time whether the surgeon would be able to heal him.
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
Ensysce Biosciences breakthrough in opioid innovation! FDA grants PF614-MPAR BTD for enhanced pain relief with overdose protection. Learn more about this cutting-edge drug.